Wall Street brokerages expect NeuBase Therapeutics, Inc. (NASDAQ:NBSE) to announce earnings of ($0.27) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for NeuBase Therapeutics’ earnings. The highest EPS estimate is ($0.26) and the lowest is ($0.27). NeuBase Therapeutics posted earnings per share of ($0.20) during the same quarter last year, which would suggest a negative year-over-year growth rate of 35%. The firm is expected to issue its next earnings report on Wednesday, December 22nd.
On average, analysts expect that NeuBase Therapeutics will report full year earnings of ($0.95) per share for the current fiscal year, with EPS estimates ranging from ($0.99) to ($0.88). For the next financial year, analysts anticipate that the firm will report earnings of ($1.03) per share, with EPS estimates ranging from ($1.34) to ($0.87). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that follow NeuBase Therapeutics.
NBSE has been the topic of a number of research reports. HC Wainwright reissued a “buy” rating and issued a $15.00 price objective on shares of NeuBase Therapeutics in a report on Monday, September 13th. Zacks Investment Research downgraded NeuBase Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, September 16th.
Shares of NBSE stock opened at $3.80 on Tuesday. The stock’s 50-day simple moving average is $3.74 and its 200-day simple moving average is $5.21. The firm has a market capitalization of $124.32 million, a PE ratio of -4.18 and a beta of -0.01. NeuBase Therapeutics has a fifty-two week low of $3.26 and a fifty-two week high of $12.89.
About NeuBase Therapeutics
NeuBase Therapeutics, Inc is a biotechnology company. It engages in the development of drugs for patients with genetic neurological disorder. The firms pipelines include Huntington’s Disease, NT0100 Program – PATrOL Enabled gamma-PNA for Huntington’s Disease, and NT0200 Program- PATrOL Enabled gamma-PNA for Myotonic Dystophy.
Featured Article: What is Net Asset Value (NAV)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NeuBase Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuBase Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.